Company Profile

We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the devastating consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. To date, we have generated five innovative, allogeneic, off-the-shelf VST therapy candidates targeting 12 different devastating viruses, the most advanced of which has successfully completed a proof-of-concept trial across five viruses and is entering initial pivotal trials.
David Hallal
Chief Executive Officer
David Hallal is a proven 30-year veteran in the biopharmaceutical industry, having grown and operated several successful biotechnology companies.
Vikas Sinha
President and Chief Financial Officer
Vikas Sinha is AlloVir's President and Chief Financial Officer and brings over 25 years of experience in executive finance roles within the biopharmaceutical industry.
Ann Leen, PhD
Chief Scientific Officer
For more than 20 years, Dr. Ann Leen has led innovative discovery and translational research focused on developing novel T cell-based therapies.
Agustin Melian, MD
Chief Medical Officer & Head of Global Medical Sciences
Prior to joining AlloVir, Dr. Augustin Melian was an SVP in both Global Clinical Development and Medical Sciences at Alexion Pharmaceuticals.
Jeroen van Beek, PhD
Chief Commercial Officer
Jeroen van Beek is responsible for commercial strategy, planning and operations at AlloVir. Before joining AlloVir, Dr. van Beek was the Chief Commercial Officer and Senior Vice-President at Tricida.
Edward Miller
General Counsel
Edward Miller has more than 25 years of diverse legal and business experience in the biotechnology and pharmaceutical industry and related fields.
Michael Paglia, MSc
Senior Vice President, CMC Operations
Michael Paglia is responsible for GMP manufacturing operations and CMC regulatory strategy for the development of AlloVir’s allogeneic T cell therapies.

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.